Altimmune

Altimmune

ALT· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -49.9% in FY2025

Vipin K. Garg, Ph.D. is the CEO of Altimmune and was paid $8.0M in FY2025 (Dec), up 32%.

Pay$100 in the stock at the end of FY21 → $39
CEO pay is from each Altimmune proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives4

See all
  1. 1Vipin K. Garg, Ph.D.FY2025
  2. 2M. Scott Harris, M.D.FY2025
  3. 3Christophe Arbet-Engels, M.D., Ph.D.FY2025
  4. 4M. Scot Roberts, Ph.D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Altimmune paid its 4 named executives $15.2M in total in FY2025 (Dec). CEO Vipin K. Garg, Ph.D. was paid $8.0M of that.

Name
Vipin K. Garg, Ph.D.Chief Executive Officer
M. Scott Harris, M.D.former Chief Medical OfficerNot disclosedNot disclosed
Christophe Arbet-Engels, M.D., Ph.D.Chief Medical OfficerNot disclosedNot disclosed
M. Scot Roberts, Ph.D.Chief Scientific OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers17

See all

The FY2025 (Dec) proxy of Altimmune names 17 peer companies for pay. Among Altimmune and these peers, CEO pay was the highest of 5 and total shareholder return was the lowest of 5.

1st highest of 5in Altimmune and its pay peers, FY2025 (Dec) by CEO pay:

$1.4M$8.0M

5th highest of 5in Altimmune and its pay peers, FY2025 (Dec) by total shareholder return:

$22$206

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Activity

Filings6

See all
Proxy statementDEF 14AMar 17, 2026FY2025
Annual report10-KMar 6, 2026FY2025
Proxy statementDEF 14AAug 15, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AAug 15, 2024FY2023
Annual report10-KMar 27, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data